Carvedilol in Alzheimer's Disease

What Is This Study About?

The purpose of this study is to determine whether taking carvedilol, a beta-blocker used to treat heart failure and high blood pressure, is associated with improvement in Alzheimer's disease compared to a placebo.

Do I Qualify To Participate in This Study?

Must have:

++Diagnosis of Alzheimer's disease by NINCDS/ADRDA criteria ++Mini-Mental State Exam (MMSE) score of 16-26; Clinical Dementia Rating (CDR) score of less than 1++May remain on current FDA-approved Alzheimer's treatments, including cholinesterase inhibitors and memantine, with stable dose for at least 3 months++May remain on antidepressant and antipsychotics medications with stable dose for at least 3 months++Knowledgeable family member or other caregiver available for all study visits

Must NOT have:

++Evidence of non-Alzheimer's dementias, including Huntington's disease, Parkinson's disease, or frontotemporal dementia++Current DSM-IV Axis I diagnoses other than dementia, including major depression, bipolar disorder, schizophrenia, anxiety disorders, alcohol abuse, or other substance abuse++Any clinically significant medical condition that could interfere with the participant's ability to safely participate in the study or to be followed++Current use of beta-blocking agents++Contraindications to use of beta-blocking agents++Clinically significant liver or kidney insufficiency

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Where Is This Study Located?

Who Sponsors This Study?

Lead: Johns Hopkins University

Collaborator Sponsor

• Mount Sinai School of Medicine

Source: ClinicalTrials.gov ID: NCT01354444